Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer

Breast Cancer, Version 3.2013

(2017) Richard L. Theriault et al.   Journal of the National Comprehensive Cancer Network

The reciprocal association between mammographic breast density, hyaluronan synthesis and patient outcome

(2015) Amro Masarwah et al.   BREAST CANCER RESEARCH AND TREATMENT

Very low mammographic breast density predicts poorer outcome in patients with invasive breast cancer

(2015) Amro Masarwah et al.   EUROPEAN RADIOLOGY

HER2 in Breast Cancer

(2014) Uma Krishnamurti et al.   ADVANCES IN ANATOMIC PATHOLOGY

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms

(2014) C. A. Drukker et al.   BREAST CANCER RESEARCH AND TREATMENT

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer

(2014) E A Rakha et al.   BRITISH JOURNAL OF CANCER

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) E. Senkus et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool

(2013) Minkyu Jung et al.   ANNALS OF SURGICAL ONCOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients

(2012) Nirmala Bhoo-Pathy et al.   EUROPEAN JOURNAL OF CANCER

Increased hyaluronan content and stromal cell CD44 associate withHER2positivity and poor prognosis in human breast cancer

(2012) Päivi Auvinen et al.   INTERNATIONAL JOURNAL OF CANCER

Heterogeneity of breast cancer: etiology and clinical relevance

(2011) Vanessa Almendro et al.   Clinical & Translational Oncology

Heterogeneity in breast cancer

(2011) Kornelia Polyak   JOURNAL OF CLINICAL INVESTIGATION

Qualitative Assessment of the Progesterone Receptor and HER2 Improves the Nottingham Prognostic Index Up to 5 Years After Breast Cancer Diagnosis

(2010) Vanya Van Belle et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom

(2009) H E Campbell et al.   BRITISH JOURNAL OF CANCER

Prognostic Models: A Methodological Framework and Review of Models for Breast Cancer

(2009) Douglas G. Altman   CANCER INVESTIGATION

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial

(2008) M. Schmidt et al.   ANNALS OF ONCOLOGY

HER2 testing in the UK: further update to recommendations

(2008) R A Walker et al.   JOURNAL OF CLINICAL PATHOLOGY